Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a diagnosis of ADHD.
This will be a randomized, double-blind, multicenter, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years of age, inclusive, with a diagnosis of ADHD. Approximately 50 subjects will be enrolled at approximately 5 sites in the United States. Subjects will be randomized (1:1) to one of two treatment groups, immediate-release (IR) viloxazine or placebo. Primary objective is to determine the safety of IR viloxazine in adults with ADHD.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| IR Viloxazine | Experimental | Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day |
|
| Placebo | Placebo Comparator | Treatment B: Placebo capsules administered orally 3 times a day |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| IR Viloxazine | Drug | One 50mg immediate-release viloxazine capsule administered orally 3 times a day (150mg total daily dose) for Week 1. Two 50mg immediate-release viloxazine capsules administered orally 3 times a day (300mg total daily dose) for Weeks 2 to 6. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of Adverse Events During 6 Weeks of Treatment | The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population | Weeks 1-6 |
| Measure | Description | Time Frame |
|---|---|---|
| Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 (End of Study) | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. |
Not provided
Inclusion criteria:
Exclusion Criteria
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jonathan Rubin, MD | Supernus Pharmaceuticals, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bradenton | Florida | 34208 | United States | |||
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | IR Viloxazine | Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day |
| FG001 | Placebo | Treatment B: Placebo administered orally 3 times a day |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Safety Population, defined as subjects who were randomly assigned to one of two treatment groups and took at least one dose of study medication
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | IR Viloxazine | Treatment A: immediate-release (IR) viloxazine capsules administered orally 3 times a day |
| BG001 | Placebo | Treatment B: Placebo administered orally 3 times a day |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Incidence of Adverse Events During 6 Weeks of Treatment | The percent of subjects who took at least one dose of immediate-release viloxazine (Safety Population; N) and who reported at least one Adverse Event (n). The percent is calculated by dividing "the number of subjects who reported at least one Adverse Event (n)" by "the number of subjects in the Safety Population (N)" and multiplying the product by 100. The higher the percentage, the higher the incidence in the Safety Population | Safety Population (N), defined as subjects who were randomly assigned to one of two treatment groups and took at least one dose of study medication. | Posted | Number | percentage of subjects | Weeks 1-6 |
|
Weeks 1-6 of Treatment
Safety Population, defined as subjects who were randomly assigned to one of two treatment groups and took at least one dose of study medication
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | IR Viloxazine | Treatment A: Immediate-release (IR) viloxazine capsules administered orally 3 times a day |
Not provided
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Dry eye | Eye disorders | MedDRA (13.0) | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jonathan Rubin, MD, Senior Vice President and Chief Medical Officer | Supernus Pharmaceuticals, Inc. | 240-403-5710 | jrubin@supernus.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Jun 30, 2010 | Jul 31, 2024 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Feb 9, 2011 | Jul 31, 2024 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D001289 | Attention Deficit Disorder with Hyperactivity |
| ID | Term |
|---|---|
| D019958 | Attention Deficit and Disruptive Behavior Disorders |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Placebo | Drug | Placebo capsules administered orally 3 times a day |
|
|
| Baseline and Week 6 |
| Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 1 | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Baseline and Week 1 |
| Change in Global Clinical Impression-Improvement (CGI-I) Score From Baseline Global Clinical Impression-Severity of Illness (CGI-S) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6 | The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The Clinical Global Impression-Severity of Illness (CGI-S) score is a single item clinician-rated assessment of the severity of subject's condition (symptoms) in relation to the clinician's total experience with patients with ADHD; it is rated on a 7-point scale with 1=Normal, not at all ill, 2=Borderline Ill, 3=Mildly Ill, 4=Moderately Ill, 5=Markedly Ill, 6=Severely Ill, 7=Among the most extremely ill patients. CGI-I scores at post-baseline visits were subtracted from CGI-S score at baseline; a change from baseline score <0 represent better outcome. | Weeks 1, 2, 3, 4, 5, and 6 |
| Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 2, Week 3, Week 4, and Week 5 | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Baseline and Weeks 2, 3, 4, and 5 |
| Change From Baseline in the Self-rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Baseline and Week 6 |
| Global Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6 | The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. A CGI-I score <4 represents a better outcome. | Weeks 1, 2, 3, 4, 5, and 6 |
| Libertyville |
| Illinois |
| 60048 |
| United States |
| Owensboro | Kentucky | 42301 | United States |
| Herndon | Virginia | 20170 | United States |
| Protocol Violation |
|
| Lost to Follow-up |
|
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Height | Mean | Standard Deviation | inches |
|
| Weight | Mean | Standard Deviation | pounds (lbs) |
|
| BMI | Mean | Standard Deviation | kilograms per square meter |
|
| OG001 |
| Placebo |
Treatment B: Placebo administered orally 3 times a day |
|
|
| Secondary | Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 (End of Study) | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Intent-to-Treat (ITT) Population (N), defined as subjects who were randomly assigned to one of two treatment groups, took at least one dose of study medication, had a valid baseline CAARS assessment (pre-dosing), and had at least one valid post-baseline CAARS assessment. | Posted | Median | Full Range | units on a scale | Baseline and Week 6 |
|
|
|
|
| Secondary | Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 1 | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Intent-to-Treat (ITT) Population (N), defined as subjects who were randomly assigned to one of two treatment groups, took at least 1 dose of study medication, had a valid baseline CAARS assessment (pre-dosing), and had at least one valid post-baseline CAARS assessment. | Posted | Median | Full Range | units on a scale | Baseline and Week 1 |
|
|
|
|
| Secondary | Change in Global Clinical Impression-Improvement (CGI-I) Score From Baseline Global Clinical Impression-Severity of Illness (CGI-S) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6 | The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. The Clinical Global Impression-Severity of Illness (CGI-S) score is a single item clinician-rated assessment of the severity of subject's condition (symptoms) in relation to the clinician's total experience with patients with ADHD; it is rated on a 7-point scale with 1=Normal, not at all ill, 2=Borderline Ill, 3=Mildly Ill, 4=Moderately Ill, 5=Markedly Ill, 6=Severely Ill, 7=Among the most extremely ill patients. CGI-I scores at post-baseline visits were subtracted from CGI-S score at baseline; a change from baseline score <0 represent better outcome. | Intent-to-Treat (ITT) Population (N), defined as subjects who were randomly assigned to one of two treatment groups, took at least 1 dose of study medication, had a valid CGI-S assessment at baseline, and had at least one valid post-baseline CGI-I assessment. | Posted | Median | Full Range | units on a scale | Weeks 1, 2, 3, 4, 5, and 6 |
|
|
|
|
| Secondary | Change From Baseline in the Investigator-Rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 2, Week 3, Week 4, and Week 5 | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Intent-to-Treat (ITT) Population (N), defined as subjects who were randomly assigned to one of two treatment groups, took at least 1 dose of study medication, and had a valid baseline CAARS assessment (pre-dosing) and at least one valid post-baseline CAARS assessment. | Posted | Median | Full Range | units on a scale | Baseline and Weeks 2, 3, 4, and 5 |
|
|
|
|
| Secondary | Change From Baseline in the Self-rated Conners' Adult Attention-Deficit/Hyperactivity Disorder (ADHD) Rating Scale (CAARS) Total Score at Week 6 | The Conners' Adult ADHD Rating Scale (CAARS) is an ADHD-specific rating scale designed and validated to assess current ADHD symptomatology in adults. The CAARS consists of 30 items, including 18 items that correspond to the 18 ADHD symptoms per the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV). The 18 items are further subdivided into two subscales: Inattention (9 items) and Hyperactivity/Impulsivity (9 items). Each item is rated on a 4-point scale from 0 (not at all, never) to 3 (very much, very frequently). The sum of 18 items yields the raw Total score (range: 0 to 54; the higher the score, the more severe the ADHD symptoms). Raw score is converted to a change from baseline (CFB) score. A lower CFB score (<0) represents a better outcome. | Intent-to-Treat (ITT) Population (N), defined as subjects who were randomly assigned to one of two treatment groups, took at least 1 dose of study medication, and had a valid baseline CAARS assessment (pre-dosing) and at least one valid post-baseline CAARS assessment. | Posted | Median | Full Range | units on a scale | Baseline and Week 6 |
|
|
|
|
| Secondary | Global Clinical Impression-Improvement (CGI-I) Score at Week 1, Week 2, Week 3, Week 4, Week 5, and Week 6 | The Global Clinical Impression-Improvement (CGI-I) scale is a single item clinician-rated assessment of how much the subject's condition (symptoms) has improved, worsened, or has not changed relative to his/her baseline state prior to the beginning of treatment; it is rated on a 7-point scale from 1 to 7, where 1=very much improved, 2=much improved, 3=minimally improved, 4=no change, 5=minimally worse, 6=much worse, 7=very much worse. A CGI-I score <4 represents a better outcome. | Intent-to-Treat (ITT) Population (N), defined as subjects who were randomly assigned to one of two treatment groups, took at least 1 dose of study medication, and at least one valid post-baseline CGI-I assessment. | Posted | Median | Full Range | units on a scale | Weeks 1, 2, 3, 4, 5, and 6 |
|
|
|
|
| 0 |
| 26 |
| 0 |
| 26 |
| 23 |
| 26 |
| EG001 | Placebo | Treatment B: Placebo administered orally 3 times a day | 0 | 25 | 0 | 25 | 18 | 25 |
| Constipation | Gastrointestinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Dry mouth | Gastrointestinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Flatulence | Gastrointestinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA (13.0) | Systematic Assessment |
|
| Fatigue | General disorders | MedDRA (13.0) | Systematic Assessment |
|
| Irritability | General disorders | MedDRA (13.0) | Systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA (13.0) | Systematic Assessment |
|
| Weight decreased | Investigations | MedDRA (13.0) | Systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA (13.0) | Systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA (13.0) | Systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA (13.0) | Systematic Assessment |
|
| Hypogeusia | Nervous system disorders | MedDRA (13.0) | Systematic Assessment |
|
| Somnolence | Nervous system disorders | MedDRA (13.0) | Systematic Assessment |
|
| Abnormal dreams | Psychiatric disorders | MedDRA (13.0) | Systematic Assessment |
|
| Initial insomnia | Psychiatric disorders | MedDRA (13.0) | Systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA (13.0) | Systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA (13.0) | Systematic Assessment |
|
Not provided
Not provided
| Change from "Baseline CGI-S Score"; Week 3 |
|
| Change from "Baseline CGI-S Score"; Week 4 |
|
| Change from "Baseline CGI-S Score"; Week 5 |
|
| Change from "Baseline CGI-S Score"; Week 6 |
|
| 0.2032 |
| Median Difference (Net) |
| -1.00 |
| 2-Sided |
| 95 |
| -2.00 |
| 0.00 |
| Superiority |
| This analysis pertains to Week 3 data. | Wilcoxon (Mann-Whitney) | 0.0677 | Median Difference (Net) | -1.00 | 2-Sided | 95 | -2.00 | 0.00 | Superiority |
| This analysis pertains to Week 4 data. | Wilcoxon (Mann-Whitney) | 0.0743 | Median Difference (Net) | -1.00 | 2-Sided | 95 | -2.00 | 0.00 | Superiority |
| This analysis pertains to Week 5 data. | Wilcoxon (Mann-Whitney) | 0.0437 | Median Difference (Net) | -1.00 | 2-Sided | 95 | -2.00 | 0.00 | Superiority |
| This analysis applies to Week 6 data. | Wilcoxon (Mann-Whitney) | 0.1209 | Median Difference (Net) | -1.00 | 2-Sided | 95 | -2.00 | 0.00 | Superiority |
| Change from Baseline score; Week 3 |
|
| Change from Baseline score; Week 4 |
|
| Change from Baseline score; Week 5 |
|
| 0.0794 |
| Median Difference (Net) |
| -4.00 |
| 2-Sided |
| 95 |
| -10.0 |
| 1.00 |
| Superiority |
| This analysis applies to Week 4 data. | Wilcoxon (Mann-Whitney) | 0.0747 | Median Difference (Net) | -6.00 | 2-Sided | 95 | -10.0 | 0.00 | Superiority |
| This analysis applies to Week 5 data. | Wilcoxon (Mann-Whitney) | 0.0545 | Median Difference (Net) | -6.50 | 2-Sided | 95 | -12.0 | 0.00 | Superiority |
| Week 3 |
|
| Week 4 |
|
| Week 5 |
|
| Week 6 |
|
| 0.4460 |
| Median Difference (Net) |
| -0.50 |
| 2-Sided |
| 95 |
| -1.00 |
| 0.00 |
| Superiority |
| Analysis pertains to Week 3 data | Wilcoxon rank-sum test | 0.0549 | Median Difference (Net) | -0.50 | 2-Sided | 95 | -1.00 | 0.00 | Superiority |
| Analysis pertains to Week 4 data | Wilcoxon rank-sum test | 0.0759 | Median Difference (Net) | -0.50 | 2-Sided | 95 | -1.00 | 0.00 | Superiority |
| Analysis pertains to Week 5 data | Wilcoxon rank-sum test | 0.0342 | Median Difference (Net) | -0.50 | 2-Sided | 95 | -1.00 | 0.00 | Superiority |
| Analysis pertains to Week 6 data | Wilcoxon rank-sum test | 0.0474 | Median Difference (Net) | -1.00 | 2-Sided | Superiority |